Fig. 1 · Structure

Documents & Downloads

Vardenafil

Cat. No. A10965 CAS 224785-90-4

PDE-5 Inhibitor

Vardenafil is a PDE5 inhibitor used for treating erectile dysfunction.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PDE5 IC50 0.7 nM
PDE6 IC50 11 nM
PDE1 IC50 180 nM
PDE3 IC50 >1000 nM
PDE4 IC50 >1000 nM

In Vitro Studies

In an intradiscal fraction containing PDE6, treatment with Vardenafil at 20 µM increased the mass distribution of PDE6 by 976 Da. In KB-C2 cells, Vardenafil at 10 µM significantly increased intracellular accumulation of [3H]-paclitaxel by 1.6-fold. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Mass spectra of the intradiscal fraction

Cell-based study · intradiscal fraction containing PDE6 [1]

An intradiscal fraction containing PDE6 was treated directly with Vardenafil at 20 µM. Mass spectra showed that the mass distribution of PDE6 increased by 976 Da.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mass spectra of PDE6mass distribution of PDE6 976 Da[1]

Literature-Reported Treatment Conditions

Treatment concentration
20 µM
Exposure duration
at 4 °C for 30 min
Method
introduced each drug directly into the intradiscal fraction
Vehicle
200 mM ammonium acetate solution such that the final concentration of DMSO was <1%
Methods and source locations

Compound reported in the paper: Vardenafil

Evidence for Vardenafil as the hydrochloride, trihydrate form reported in the paper, not the free base/neutral form supplied as A10965; no salt equivalence, dose conversion or lot validation.

Results > Off-target drug binding at the single proteoform level (S115, S116); Methods > Drug binding (S208, S209, S211, S212); Fig. 4 legend (S242)

Mass spectra of PDE6: Mass spectra of PDE6; comparator: Controls contained no drug but were diluted with the equivalent DMSO-containing buffer. — Results > Off-target drug binding at the single proteoform level (S116); Fig. 4 legend (S242)

Intracellular paclitaxel accumulation in KB-C2 cells

Cell-based study · KB-C2 [2]

KB-C2 cells were incubated with Vardenafil at 10 µM. Vardenafil significantly increased intracellular accumulation of [3H]-paclitaxel by 1.6-fold.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
intracellular accumulation of [3H]-paclitaxelintracellular accumulation of [3H]-paclitaxel 1.6-fold[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
preincubated with or without the reversing agents for 1 h at 37°C
Method
incubating cells
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Vardenafil

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > [3H]-paclitaxel accumulation and efflux (S25, S26); Results > Vardenafil significantly increases the accumulation of intracellular paclitaxel in ABCB1-overexpressing cells by inhibiting drug efflux (S76, S78)

intracellular accumulation of [3H]-paclitaxel: intracellular accumulation of [3H]-paclitaxel; comparator: in the absence and presence of vardenafil — Results > Vardenafil significantly increases the accumulation of intracellular paclitaxel in ABCB1-overexpressing cells by inhibiting drug efflux (S78)

In Vivo Studies

In male Zucker diabetic fatty rats receiving a Purina diet, daily Vardenafil at 10 mg/kg body weight (BW) via drinking water yielded a reported fractional area of 42.3 ± 1.4%, compared with 20.8 ± 1% in vehicle-treated diabetic controls. Cardiomyocyte passive tension was 1.30 ± 0.12 kN/m2 with Vardenafil versus 1.98 ±0.12 kN/m2 in vehicle-treated diabetic controls. [3]

Fractional area measurements in diabetic rats

Animal study · Male 7-week-old Zucker diabetic fatty (ZDF) rats; vardenafil-treated diabetic rats (ZDF + Vard; n = 8) [3]

Male Zucker diabetic fatty rats receiving a Purina diet were treated daily with Vardenafil at 10 mg/kg body weight (BW) via drinking water. The reported fractional area was 42.3 ± 1.4% in treated diabetic rats versus 20.8 ± 1% in vehicle-treated diabetic controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cGMP assays; fractional areas (%)cGMP fractional area 42.3 ± 1.4%[3]

Conditions shared by the study groups

Route
per os; via drinking water
Treatment course
Daily; initiated at the age of 7 weeks and continued until the end of the experimental period
Vehicle
0.01 M/L citrate buffer
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vardenafil 10 mg/kg body weight (BW)vehicle-treated diabetic (ZDF; n = 7)LVZDF, 20.8 ± 1%; LVZDF + Vard, 42.3 ± 1.4%[3]
Vardenafil 10 mg/kg body weight (BW)
Model: Male 7-week-old Zucker diabetic fatty (ZDF) rats; vardenafil-treated diabetic rats (ZDF + Vard; n = 8)
Methods and source locations

Compound reported in the paper: Vardenafil

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Animal Model (S3, S4, S5, S6); Figure 1 legend (S73, S74)

cGMP assays; fractional areas (%): cGMP assays; fractional areas (%); comparator: vehicle-treated diabetic (ZDF; n = 7) — Figure 1 legend (S73, S74)

Vardenafil 10 mg/kg body weight (BW) · 2. Materials and Methods > 2.1. Animal Model (S6); Figure 1 legend (S73)

Cardiomyocyte passive tension in diabetic rats

Animal study · Male 7-week-old Zucker diabetic fatty (ZDF) rats; vardenafil-treated diabetic rats (ZDF + Vard; n = 8) [3]

Male Zucker diabetic fatty rats receiving a Purina diet were treated daily with Vardenafil at 10 mg/kg body weight (BW) via drinking water. Cardiomyocyte passive tension was 1.30 ± 0.12 kN/m2 in treated diabetic rats versus 1.98 ±0.12 kN/m2 in vehicle-treated diabetic controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cardiomyocyte passive tension (Fpassive); left (A,C)Reported result LVZDF, 1.98 ±0.12 kN/m2; LVZDF + Vard, 1.30 ± 0.12 kN/m2[3]

Conditions shared by the study groups

Route
per os; via drinking water
Treatment course
Daily; initiated at the age of 7 weeks and continued until the end of the experimental period
Vehicle
0.01 M/L citrate buffer
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vardenafil 10 mg/kg body weight (BW)vehicle-treated diabetic (ZDF; n = 7)LVZDF, 1.98 ±0.12 kN/m2; LVZDF + Vard, 1.30 ± 0.12 kN/m2[3]
Vardenafil 10 mg/kg body weight (BW)
Model: Male 7-week-old Zucker diabetic fatty (ZDF) rats; vardenafil-treated diabetic rats (ZDF + Vard; n = 8)
Reported limits: Removed after verification: value.
Methods and source locations

Compound reported in the paper: Vardenafil

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Animal Model (S3, S4, S5, S6); Figure 2 legend (S77, S81)

Cardiomyocyte passive tension (Fpassive); left (A,C): Cardiomyocyte passive tension (Fpassive); left (A,C); comparator: vehicle-treated diabetic (ZDF; n = 7) — Figure 2 legend (S77, S81)

Vardenafil 10 mg/kg body weight (BW) · 2. Materials and Methods > 2.1. Animal Model (S6); Figure 2 legend (S81)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 224785-90-4
Applications PDE-5 Inhibitor
Formula C23H32N6O4S.HCl.3(H2O)
Molecular Weight 579.1
Synonyms Vardenafil hydrochloride trihydrate
SMILES
CCCC1=NC(=C2N1NC(=NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Lutomski CA, Bennett JL, El-Baba TJ, et al. Defining proteoform-specific interactions for drug targeting in a native cell signalling environment. Nat Chem (2025). PMID: 39806141 DOI: 10.1038/s41557-024-01711-w Source material
  2. [2] Ding PR, Tiwari AK, Ohnuma S, et al. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One (2011). PMID: 21552528 DOI: 10.1371/journal.pone.0019329 Source material
  3. [3] Bódi B, Kovács Á, Gulyás H, et al. Long-Term PDE-5A Inhibition Improves Myofilament Function in Left and Right Ventricular Cardiomyocytes through Partially Different Mechanisms in Diabetic Rat Hearts. Antioxidants (Basel) (2021). PMID: 34829647 DOI: 10.3390/antiox10111776 Source material

Added to your cart

View Cart Checkout
Loading...